SecBot SecBot
424B5 ·Filed May 29, 2026

EXOZ

EXOZYMES INC.
BEARISH
Impact 7/10
Horizondays Processed5mo ago SEC0001493152-26-025698
Notable filing: 424B5
Actionable Insight ▼ Bearish

The dilutive offering, combined with a going-concern warning and a conflicted underwriter that is also the largest shareholder, signals severe capital needs. Monitor the final pricing and share count in the subsequent 424B5 filing — the actual dilution magnitude will determine the near-term stock impact. The 12-month company lock-up and 6-month insider lock-up provide some near-term supply relief post-offering.

DirectionBearish
Confidencehigh
Horizondays
Final — all horizons settled through T+60d
EXOZ ▼ -29.41% at T+60d
SHORT call ✓ call won +29.41% · α vs SPY +30.59% · entry $9.85 → $6.95
Entry = T+0 close
May 29, 2026
via day close
T+1d
-1.78%
call +1.78% · α +2.04%
$9.67
settled 5mo ago
T+5d
-5.13%
call +5.13% · α +2.61%
$9.34
settled 5mo ago
T+20d
-14.47%
call +14.47% · α +12.68%
$8.42
settled 4mo ago
T+60d
-29.41%
call +29.41% · α +30.59%
$6.95
settled 2mo ago

Price Chart

Loading chart...

Executive Summary

EXOZ is conducting a dilutive underwritten public offering of common stock and warrants under its existing $50M shelf registration. All key terms (share count, price, proceeds) are placeholder amounts, but the offering structure is confirmed: units of 2 shares + 1 warrant, with warrants exercisable at 125% of the offering price for 2 years. The underwriter MDB Capital is also the company's largest shareholder (47.79%), creating a FINRA Rule 5121 conflict of interest. The filing explicitly discloses substantial doubt about going concern and warns of immediate and substantial dilution for new investors.

Key Facts

  • Dilutive offering of common stock and warrants under $50M shelf registration (S-3 filed Jan 2026)
  • Units consist of 2 shares + 1 warrant; warrant exercise price set at 125% of offering price, 2-year term
  • Underwriter MDB Capital is the largest shareholder (47.79%) and has board representation — FINRA conflict of interest declared
  • Company discloses substantial doubt about ability to continue as a going concern in the risk factors
  • Public float is ~$15.2M (based on 4.6M affiliate-held shares and $11.70 reference price), limiting primary offering size under S-3 I.B.6 to ~$5M
  • 8,478,992 shares outstanding pre-offering; offering size and resulting dilution are undisclosed (placeholder amounts)
  • 12-month company lock-up and 6-month insider lock-up from closing
  • Proceeds intended for NCT business development, R&D, and working capital

Financial Impact

Offering size and pricing are undisclosed (placeholder amounts). Based on public float of ~$15.2M and S-3 I.B.6 limitation, the primary offering is capped at roughly $5M. Underwriting discount is 7% plus up to $100K expenses and $175K QIU fee. Immediate and substantial dilution is explicitly warned.

dilutionshare countcash position

Risk Factors

  • Immediate and substantial dilution to existing shareholders
  • Going-concern risk — company may not survive without this capital raise
  • Conflicted underwriter (MDB Capital owns 47.79% and controls board seats) raises governance concerns
  • Warrant overhang (2-year term, exercisable at 125% of offering price) could pressure stock
  • No trading market for warrants; liquidity risk for warrant holders

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
424B5 Filing (Primary)0001493152-26-025698
Document: 0001493152-26-025698-index-headers.html0001493152-26-025698
Document: 0001493152-26-025698-index.html0001493152-26-025698
Document: 0001493152-26-025698.txt0001493152-26-025698
11 reports for EXOZ
Performance horizon
100% Hit rate @ T+20 5 of 5 directional calls Went positive at some point 5 of 5 best @ T+20▲ +48.24%Jun 30, 2026
Filters
Rows
Reports for EXOZ — sortable, filterable
TypeNow
Oct 9, 2026
17d ago
8-K
NEUTRAL ★ 2/10
$5.25awaiting T+20—$3.75 (−28.57%)
Sep 28, 2026
28d ago
DEFA14A
NEUTRAL ★ 3/10
$6.10awaiting T+20—$3.75 (−38.52%)
Sep 28, 2026
28d ago
DEF 14A
NEUTRAL ★ 3/10
$6.10awaiting T+20—$3.75 (−38.52%)
Sep 18, 2026
5w ago
8-K
NEUTRAL ★ 1/10
$6.44 $4.09▼ −36.44%▼ −36.65%$3.75 (−41.72%)
Jun 30, 2026
16w ago
424B5
BEARISH ★ 6/10
$8.50 $4.40▲ +48.24%▲ +46.05%$3.75 (+55.88%)
Jun 25, 2026
17w ago
8-K
NEUTRAL ★ 4/10
$8.03 $4.70▼ −41.47%▼ −42.73%$3.75 (−53.30%)
Jun 17, 2026
18w ago
8-K
BEARISH ★ 6/10
$7.83 $6.22▲ +20.56%▲ +21.09%$3.75 (+52.11%)
Jun 8, 2026
20w ago
8-K
BEARISH ★ 7/10
$8.62 $8.14▲ +5.57%▲ +7.20%$3.75 (+56.50%)
Jun 8, 2026
20w ago
424B5
BEARISH ★ 6/10
$8.62 $8.14▲ +5.57%▲ +7.20%$3.75 (+56.50%)
Jun 4, 2026
20w ago
424B5
BEARISH ★ 7/10
$9.35 $8.48▲ +9.30%▲ +7.93%$3.75 (+59.89%)
Showing 10 of 11

US Market Status

Market Closed — Opens in 3h 53m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 29, 2026